Analysis of The Cancer Genome Atlas (TCGA) Research Network (Cerami et al, 2012) pancreatic adenocarcinoma provisional dataset revealed that survival of patients with genomic amplification or significantly elevated mRNA for ROCK1 and/or ROCK2, or truncating ROCK1 mutations similar to previously described cancer‐associated activating ROCK1 truncation mutations (Lochhead et al, 2010), was significantly shorter than in patients without ROCK1/ROCK2 alterations (median survival periods: 21 months for patients without alterations versus 17 months, P = 0.037) (Fig 1B). This evidence concerns the gene ROCK2 and pancreatic adenocarcinoma.